Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (noted as Tempest Therapeutics, Inc. in metadata) on December 11, 2014, covering events that occurred on December 9, 2014. The filing details significant executive appointments, promotions, and the granting of unregistered equity securities as inducements for new roles and employment extensions.
Key Financial Metrics and Equity Grants
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial data relates to equity compensation grants made at a stock price of $32.36 per share:
- David P. Harding (New Chief Commercial Officer): Granted an option to purchase 343,000 shares at $32.36/share. Vesting is over four years (25% at one year, then quarterly).
- Arthur Tzianabos, Ph.D. (Promoted to President): Granted an option to purchase 270,000 shares at $32.36/share. Vesting is over four years. Base salary increased from $350,000 to $425,000; target cash bonus increased from 40% to 50% of salary.
- Michelle Dipp, M.D., Ph.D. (CEO): Granted an option to purchase 200,000 shares at $32.36/share. Also received Restricted Stock Units (RSUs) for 30,902 shares (time-based) and a target of 15,451 shares (performance-based, up to 23,176 shares). These awards are in lieu of cash compensation.
Material Changes
The filing reports the following material changes in corporate governance and compensation:
- Executive Appointments: David P. Harding appointed as Chief Commercial Officer; Arthur Tzianabos promoted from Chief Scientific Officer to President.
- Compensation Adjustments: Significant increases in base salary and bonus targets for Dr. Tzianabos. Dr. Dipp's employment agreement was amended to extend terms and provide equity awards in lieu of cash.
- Unregistered Sales: The issuance of the stock option to Mr. Harding was exempt from registration under Section 4(a)(2) of the Securities Act as a transaction not involving a public offering.
Outlook, Risks, and Unusual Items
The filing does not provide forward-looking guidance, revenue outlook, or general risk factors. Specific contingencies related to the equity grants include:
- Change of Control Acceleration: For Mr. Harding, full vesting accelerates if employment is terminated without cause or he resigns for good reason within one year of a change of control. For Dr. Dipp, time-based RSUs and options vest immediately upon a change in control.
- Termination Provisions: Dr. Dipp is entitled to a tax gross-up if payments become subject to excise taxes under Sections 280G and 4999 of the Internal Revenue Code. Upon termination without cause or resignation for good reason, unvested portions of her awards that would have vested in the following six months will vest.
Investor Verification Checklist
- Verify the exact number of shares authorized under the 2012 Stock Incentive Plan versus the separate Inducement Award granted to Mr. Harding.
- Confirm the specific performance-based vesting conditions attached to Dr. Dipp's 15,451 target RSUs.
- Review the full text of the "Offer Letter" and "CEO Employment Agreement" to understand the precise definitions of "good reason" and "without cause."
- Check subsequent filings for any dilution impact from the exercise of these options or vesting of RSUs.